Takenori Ikoma, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 9 | 2024 | 11837 | 0.630 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2024 | 1338 | 0.630 |
Why?
|
| Nutrition Assessment | 1 | 2021 | 738 | 0.590 |
Why?
|
| Pulmonary Veins | 1 | 2022 | 757 | 0.520 |
Why?
|
| Cardiomyopathies | 2 | 2022 | 2068 | 0.430 |
Why?
|
| Oligopeptides | 1 | 2019 | 1193 | 0.430 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 2132 | 0.390 |
Why?
|
| Catheter Ablation | 1 | 2022 | 2787 | 0.310 |
Why?
|
| Exercise Test | 3 | 2024 | 2185 | 0.280 |
Why?
|
| Anaerobic Threshold | 1 | 2024 | 51 | 0.230 |
Why?
|
| Sweat | 1 | 2024 | 57 | 0.230 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 5186 | 0.210 |
Why?
|
| Xanthine Dehydrogenase | 1 | 2021 | 18 | 0.190 |
Why?
|
| Oximetry | 1 | 2024 | 458 | 0.180 |
Why?
|
| Exercise Tolerance | 2 | 2024 | 841 | 0.180 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 5189 | 0.180 |
Why?
|
| Oxygen Consumption | 2 | 2024 | 1872 | 0.170 |
Why?
|
| Lactic Acid | 1 | 2024 | 1137 | 0.160 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2022 | 511 | 0.160 |
Why?
|
| Recurrence | 2 | 2022 | 8492 | 0.150 |
Why?
|
| NAD | 1 | 2022 | 618 | 0.150 |
Why?
|
| Dynamins | 1 | 2018 | 139 | 0.140 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2024 | 1060 | 0.140 |
Why?
|
| Scleroderma, Systemic | 1 | 2020 | 346 | 0.140 |
Why?
|
| Aftercare | 1 | 2023 | 915 | 0.130 |
Why?
|
| Myocytes, Cardiac | 2 | 2022 | 1672 | 0.130 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2024 | 982 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 13631 | 0.130 |
Why?
|
| Heart Atria | 1 | 2022 | 1363 | 0.130 |
Why?
|
| Cardiomegaly | 1 | 2018 | 590 | 0.120 |
Why?
|
| Amyloidosis | 1 | 2022 | 883 | 0.120 |
Why?
|
| Reactive Oxygen Species | 1 | 2021 | 2141 | 0.110 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2018 | 855 | 0.100 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2022 | 1399 | 0.100 |
Why?
|
| Oxygen | 1 | 2022 | 4246 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 1604 | 0.080 |
Why?
|
| Mitochondria | 1 | 2022 | 3669 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2019 | 3988 | 0.060 |
Why?
|
| Docosahexaenoic Acids | 2 | 2022 | 916 | 0.060 |
Why?
|
| Humans | 15 | 2024 | 765926 | 0.060 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2022 | 54 | 0.050 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2024 | 156 | 0.050 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 2022 | 30 | 0.050 |
Why?
|
| Prognosis | 2 | 2023 | 29890 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 6544 | 0.050 |
Why?
|
| Middle Aged | 5 | 2024 | 223016 | 0.050 |
Why?
|
| Mediastinum | 1 | 2022 | 271 | 0.050 |
Why?
|
| NADP | 1 | 2022 | 228 | 0.040 |
Why?
|
| Prealbumin | 1 | 2022 | 264 | 0.040 |
Why?
|
| Sirtuin 1 | 1 | 2022 | 247 | 0.040 |
Why?
|
| Aged | 5 | 2024 | 171163 | 0.040 |
Why?
|
| Stroke Volume | 2 | 2024 | 5595 | 0.040 |
Why?
|
| Rats, Inbred Dahl | 1 | 2018 | 34 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2024 | 54807 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2022 | 65194 | 0.040 |
Why?
|
| Hypertension | 1 | 2018 | 8616 | 0.040 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2022 | 565 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2024 | 2075 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2022 | 1143 | 0.040 |
Why?
|
| Female | 5 | 2024 | 396141 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2020 | 1377 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2022 | 81537 | 0.030 |
Why?
|
| ROC Curve | 1 | 2024 | 3612 | 0.030 |
Why?
|
| Sodium Chloride | 1 | 2018 | 578 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2022 | 1459 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2021 | 3583 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2020 | 1670 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 2701 | 0.030 |
Why?
|
| Male | 5 | 2024 | 363815 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 1937 | 0.020 |
Why?
|
| Echocardiography | 1 | 2024 | 5040 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2020 | 4186 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2021 | 4498 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2023 | 3460 | 0.020 |
Why?
|
| Myocardium | 1 | 2022 | 4764 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2022 | 3586 | 0.020 |
Why?
|
| Heart | 1 | 2022 | 4419 | 0.020 |
Why?
|
| Hospitals | 1 | 2021 | 3886 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 10380 | 0.020 |
Why?
|
| Registries | 1 | 2023 | 8346 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2018 | 8530 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 18292 | 0.010 |
Why?
|
| Rats | 1 | 2018 | 23708 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 20690 | 0.010 |
Why?
|
| Animals | 2 | 2022 | 168735 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 59496 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 12235 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 81782 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 36547 | 0.010 |
Why?
|
| Adult | 1 | 2024 | 223088 | 0.010 |
Why?
|